Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to acquire all rights to bermekimab, an investigational compound for certain skin disorders, from XBiotech, in a deal worth up to $1.35 billion, as per the latest pharma acquisition news. Bermekimab, which is an anti-IL-1alpha monoclonal antibody (mAb), […]
AMZEEQ FDA approval : Israeli specialty pharma company Foamix Pharmaceuticals has bagged approval from the US Food and Drug Administration (FDA) for AMZEEQ (minocycline) topical foam, 4% for the treatment of moderate to severe acne. Previously known as FMX101, AMZEEQ has been indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne […]
In a significant move within the pharmaceutical industry, Spanish pharmaceutical company Almirall has finalised its $550 million acquisition of five dermatology medications from Allergan’s Medical Dermatology unit in the United States. This strategic acquisition, first announced in August 2018, aims to expand Almirall’s footprint in the US dermatology market. Acquisition Details and Financial Implications The […]
Aurobindo Pharma, a prominent Indian pharmaceutical company, has agreed to a significant acquisition from Sandoz US, a division of the Swiss pharmaceutical giant Novartis. The deal, valued at approximately $1 billion, involves the purchase of Sandoz’s dermatology business and a diverse portfolio of oral solid products, along with commercial and manufacturing infrastructure. The transaction terms […]
In a strategic move within the pharmaceutical industry, Sandoz US, a subsidiary of the Swiss-based Novartis, has announced the sale of its dermatology and oral solids businesses to Aurobindo Pharma, an Indian pharmaceutical giant. The deal, which includes a $900 million cash payment and potential earn-outs of $100 million, marks a significant reshaping of Sandoz’s […]
Ortho Dermatologics, a division of Bausch Health Companies, has achieved a significant milestone with the FDA approval of Altreno lotion (tretinoin 0.05%) for the treatment of acne vulgaris in patients aged 9 years and older. This approval marks Altreno as the first tretinoin formulation available in a lotion format, designed to enhance patient experience with […]